Sugi Predict

Sugi Predict / Compounds / SCHEMBL1624736

SCHEMBL1624736

SCHEMBL1624736

CCc1nc2c(C)nc(C)cc2n1-c1ccc(CCO)cc1

nearest known ligand 0.57

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ PTGER4 P35408 1/20 0.57
▸ FAAH O00519 1/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ TP53 P04637 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ GPR4 P46093 1/20 0.33
▸ ESR1 P03372 1/20 0.33
▸ ESR2 Q92731 1/20 0.33
▸ CYP4F2 P78329 1/20 0.32
▸ CYP4A11 Q02928 1/20 0.32
▸ PDE4B Q07343 1/20 0.32
▸ GRM5 P41594 1/20 0.31
▸ GRM1 Q13255 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30513699 1.00 PTGER4 (0.57) PTGER4FAAHMEN1KMT2ATP53
SCHEMBL1624348 0.90 PTGER4 (0.49) PTGER4TP53MAPTESR1ESR2
SCHEMBL21741607 0.90 PTGER4 (0.57) PTGER4FAAHMEN1KMT2ATP53
SCHEMBL1624672 0.87 PTGER4 (0.55) PTGER4FAAHMEN1KMT2ATP53
SCHEMBL1626358 0.87 PTGER4 (0.55) PTGER4FAAHMEN1KMT2ATP53
SCHEMBL30224999 0.87 PTGER4 (0.55) PTGER4FAAHMEN1KMT2ATP53
SCHEMBL23876632 0.87 PTGER4 (0.60) PTGER4FAAHMEN1KMT2ATP53
Hydrochloric Acid SCHEMBL1999779 0.86 PTGER4 (0.54) PTGER4FAAHMEN1KMT2AGPR4
SCHEMBL1626154 0.86 PTGER4 (0.46) PTGER4FAAHTP53MAPT
SCHEMBL21741601 0.85 PTGER4 (0.61) PTGER4FAAHTP53MAPTGPR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116496274-A Preparation method of EP4 receptor antagonist 江苏天和制药有限公司 2023-07-28 — — CN claimed
CN-116496274-A Preparation method of EP4 receptor antagonist 江苏天和制药有限公司 2023-07-28 — — CN disclosed
CN-116496274-A Preparation method of EP4 receptor antagonist 江苏天和制药有限公司 2023-07-28 — — CN disclosed
WO-2023012820-A1 A PROCESS FOR THE PREPARATION OF GRAPIPRANT AND ITS INTERMEDIATES ZENFOLD SUSTAINABLE TECHNOLOGIES PRIVATE LIMITED (IN) 2023-02-09 — — WO disclosed
US-11254675-B2 Process for preparation of grapiprant CADILA HEALTHCARE LIMITED (IN) 2022-02-22 — — US disclosed
US-20210347776-A1 PROCESS FOR PREPARATION OF GRAPIPRANT CADILA HEALTHCARE LIMITED (IN) 2021-11-11 — — US disclosed
US-20210079000-A1 PROCESS FOR PREPARATION OF GRAPIPRANT CADILA HEALTHCARE LIMITED (IN) 2021-03-18 — — US disclosed
US-7960407-B2 Crystal forms of an imidazole derivative REQUALIA PHARMA INC. (JP) 2011-06-14 — — US disclosed
US-7928119-B2 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases PFIZER INC. (US) 2011-04-19 — — US disclosed
EP-1861400-B1 CRYSTAL FORMS OF AN IMIDAZOLE DERIVATIVE RAQUALIA PHARMA INC (JP) 2010-05-26 — — EP disclosed
US-6710054-B2 CONTAINING SULFONYLAMINOCARBONYL GROUPS; PROSTAGLANDIN INHIBITORS PFIZER INC 2004-03-23 — — US disclosed
CN-1476448-A Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents ������ҩ�����޹�˾ 2004-02-18 — — CN disclosed
US-20030236260-A1 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases SHIMOJO MASATO 2003-12-25 — — US disclosed
WO-2003086371-A2 USE OF EP4 RECEPTOR LIGANDS IN THE TREATMENT OF IL-6 INVOLVED DISEASES PFIZER JAPAN INC. (JP) 2003-10-23 — — WO disclosed
EP-1326864-A2 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 2003-07-16 — — EP disclosed
EP-1326606-A2 EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS PFIZER PHARMACEUTICALS INC. (JP) 2003-07-16 — — EP disclosed
US-20020107273-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents ASKAT INC. (JP) 2002-08-08 — — US disclosed
US-20020077329-A1 EP4 receptor inhibitors to treat rheumatoid arthritis PFIZER PHARMACEUTICALS INC. (JP) 2002-06-20 — — US disclosed
WO-2002032422-A2 EP4 RECEPTOR INHIBITORS TO TREAT RHEUMATOID ARTHRITIS PFIZER PHARMACEUTICALS INC. (JP) 2002-04-25 — — WO disclosed
WO-2002032900-A2 ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS PFIZER PHARMACEUTICALS INC. (JP) 2002-04-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210347776-A1 PROCESS FOR PREPARATION OF GRAPIPRANT ADCYAP1R1, GANC, DRD4 PTGER4 271/4885FAAH 844/4885MEN1 4162/4885
US-20020107273-A1 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents PTGS1, PTGS2, OPRM1 PTGER4 51/4885FAAH 146/4885MEN1 3912/4885
US-11254675-B2 Process for preparation of grapiprant ADCYAP1R1, GANC, DRD4 PTGER4 271/4885FAAH 844/4885MEN1 4162/4885
US-20030236260-A1 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases PTGER4, PTGER1, IL6 PTGER4 1/4885FAAH 585/4885MEN1 4475/4885
US-20210079000-A1 PROCESS FOR PREPARATION OF GRAPIPRANT ADCYAP1R1, GANC, DRD4 PTGER4 271/4885FAAH 844/4885MEN1 4162/4885
US-20020077329-A1 EP4 receptor inhibitors to treat rheumatoid arthritis PTGER4, PTGER1, PTGER2 PTGER4 1/4885FAAH 102/4885MEN1 4826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.